Monitor FDA feedback on the upcoming IDE submission in Q2 2026, as regulatory progress is critical for clinical advancement. The reduced cash runway (through Spring 2026) suggests potential need for additional financing later in the year if trials proceed as planned.
Price Chart
Executive Summary
Glucotrack reported full-year 2025 financial results showing a reduced net loss of $19.4 million compared to $22.6 million in 2024, driven by lower non-cash expenses. The company strengthened its IP portfolio with three new USPTO patents and raised $4.0 million through a private placement. Cash of $7.4 million is expected to fund operations through Spring 2026, supporting the planned IDE submission for U.S. clinical trials.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $19.4 million vs $22.6 million in 2024, primarily due to $7.5 million in lower non-cash losses from debt settlement and derivative warrants.
- Cash and cash equivalents were $7.4 million as of December 31, 2025, up from $5.6 million at the end of 2024, funded by $17.0 million in financing activities.
- Company completed a $4.0 million private placement in December 2025 with a single institutional investor.
- Three new USPTO patents issued for Glucotrack's CBGM technology, covering sensor chemistry, intravascular lead design, and low-power electronics.
- Company plans to submit an Investigational Device Exemption (IDE) to the FDA in Q2 2026 for a U.S. feasibility study, targeting trial launch in H2 2026.
Financial Impact
Net loss decreased by $3.2 million YoY; $4.0 million raised via private placement; $17.0 million in total financing proceeds in 2025.
Risk Factors
- Cash runway extends only through Spring 2026, creating near-term funding risk ahead of clinical trial initiation.
- Net loss reduction driven by non-recurring non-cash items, not operational improvement; R&D and G&A expenses increased year-over-year.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-013654 |
| Document: form8-k.htm | 0001493152-26-013654 |
| Document: 0001493152-26-013654-index-headers.html | 0001493152-26-013654 |
| Document: 0001493152-26-013654-index.html | 0001493152-26-013654 |
| Document: 0001493152-26-013654.txt | 0001493152-26-013654 |
| 8-K Data (Synthetic) | 0001493152-26-013654 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $0.6081 | awaiting T+60 | — | — |
Oct 19, 2026 6d ago | 8-K | $0.6511 | awaiting T+60 | — | — |
Oct 13, 2026 12d ago | S-1/A | $0.8873 | awaiting T+60 | — | — |
Oct 13, 2026 12d ago | 425 | $0.8873 | awaiting T+60 | — | — |
Sep 28, 2026 27d ago | 8-K | $1.74 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | — |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers